Ongoing studies explore potential targeted therapeutic options for gynecological cancers, including the targeting of epidermal growth factor receptor (EGFR), androgen receptor, poly ADP-ribose polymerase (PARP), and vascular endothelial growth factor (VEGF) (Luque-Bolivar et al, 2020). This evidence concerns the gene VEGFA and female reproductive organ cancer.